Drawing for ENEBEX

USPTO serial 87351149

ENEBEX

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
CHANG, KATHERINE S
Law office
TTAB

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 604: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with ENEBEX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Stephen R. Barrese, Esq.

STEPHEN R BARRESE DILWORTH & BARRESE LLP1000 WOODBURY ROADSUITE 405WOODBURY, NY 11797

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for medical use, namely, pharmaceutical preparations for immunoregulation, for treatment of autoimmune diseases, for use as anti-cancer agents, for treatment of cancer, for treatment of tumors, for treatment of central nervous system disorders and for treatment of metabolic diseases; pharmaceutical preparations for treating human immune diseases and conditions; pharmaceutical preparations for treating inflammatory diseases and conditions; pharmaceutical preparations for treating arthritis; pharmaceutical preparations for treating rheumatoid arthritis; pharmaceutical preparations for treating psoriatic arthritis; pharmaceutical preparations for treating ankylosing spondylitis; pharmaceutical preparations for treating psoriasis; pharmaceutical preparations for treating polyarticular juvenile idiopathic arthritis; pharmaceutical preparations for treating enthesitis-related arthritisABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 7, 2018MAB4ABANDONMENT NOTICE MAILED - INTER PARTES DECISION—
Mar 7, 2018ABN4ABANDONMENT - AFTER INTER PARTES DECISION—
Mar 7, 2018OP.TOPPOSITION TERMINATED NO. 999999—
Mar 7, 2018OP.SOPPOSITION SUSTAINED NO. 999999—
Nov 28, 2017OP.IOPPOSITION INSTITUTED NO. 999999—
Aug 9, 2017ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Aug 1, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 1, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 12, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 24, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 24, 2017XAECEXAMINER'S AMENDMENT ENTERED—
May 24, 2017GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
May 24, 2017GNEAEXAMINERS AMENDMENT E-MAILED—
May 24, 2017CNEAEXAMINERS AMENDMENT -WRITTEN—
May 22, 2017DOCKASSIGNED TO EXAMINER—
Mar 6, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 2, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance